Jim Cassella
Company: Concert Pharmaceuticals
Job title: Chief Development Officer
Seminars:
Speaker Q&A panel 1:10 pm
day: Day Two
Update on Long-Term Safety & Efficacy of CTP-543, an Oral JAK Inhibitor, for the Treatment of Alopecia Areata 11:55 am
CTP-543 was dosed for 24 weeks in three Phase 2 trials; eligible patients subsequently enrolled in a long-term, open-label extension trial with >130 patients treated for more than 1 year. Hair regrowth assessed by SALT has been sustained or improved in the vast majority of patients in the extension study relative to the Phase 2…Read more
day: Day Two